

RATIONALE

Adeno-pituitary tumour represents a complex disease, with a wide spectrum of clinical manifestations, according to the ability of secreting different hormones or pro-hormones and of invading the neighbouring anatomical structures, such as the same pituitary gland, the optical chiasm, the cavernous sinus, the bone, the third ventricle and the ventricular system. In the most recent years, a better definition of these neoplasia was researched in order to identify biomarkers able to predict the natural history of adeno-pituitary tumour and their responsiveness to the different treatments.

Until now, the classifications of the neoplasms arising from adeno-hypophysial cells have been misleading because of their poor reproducibility and their weak ability in predicting the aggressiveness, the prognosis, and the outcome of these neoplasia. The 2004 WHO classification distinguished pituitary adenoma in typical and atypical ones according to the detection of mitoses and according to the expression of Ki-67 or p53. The 2004 WHO classification however failed in identifying pituitary tumours refractory to medical, surgical or radiation therapies or able to regrowth or to metastasize. Similarly, the new 2017 WHO classification lacks in defining the prognosis of pituitary neoplasia. Invasive, recurrent and proliferative pituitary neoplasia cause significant morbidity, in particular in cases of persistence hormonal hyper-secretion. Both long term hormonal hyper-secretion and hypopituitarism, in absence of an adequate hormonal replacement therapy, are associated to increased morbidity and mortality for their systemic complications.

Therefore, recently, adeno-pituitary tumours were included in neuroendocrine tumours (NETs). This new terminology of pituitary neuroendocrine tumor (PitNET) may reflect better the potential for aggressiveness and malignant behaviour and of these neoplasia. Anyway a consensus on PitNETs was not yet reached.

On this basis, in the recent years, a wide number of research investigated the genetic, molecular and biological features of PitNETs, in order to predict the clinical behaviour of these neoplasia and to personalize the treatments in not-secreting and secreting tumors as prolactinoma, acromegaly, Cushing disease. The current event has the aim of updating participants on the latest biological, genetic and clinical acquisitions on PitNET and on their impact in the management of PitNET affected patients according to the new knowledge, that requires a close clinical collaboration between pathologists, neurosurgeons and endocrinologists.

The meeting is part of the teaching activities of the Master Degree in Diagnosis and Treatment of pituitary disease (2022) - Faculty of Medicine, Università Cattolica del Sacro Cuore, Rome.

DIRECTOR Prof. ALFREDO PONTECORVI
Professor of Endocrinology
Fondazione Policlinico Universitario A. Gemelli
Università Cattolica del Sacro Cuore, Rome

SEDE

Hotel Donna Camilla Savelli
Via Garibaldi 27, 00153 Roma RM

RESPONSABILE SCIENTIFICO

Prof.ssa Laura De Marinis

Coordinatore Scientifico del Master Universitario di II Livello
in diagnosi e terapia delle patologie ipotalamo ipofisarie
Policlinico Universitario A. Gemelli, Roma

SEGRETERIA SCIENTIFICA

Coordinatori

Antonio Bianchi, Antonella Giampietro

Sabrina Chiloiro, Domenico Milardi

U.O.S. di Patologia Ipotalamo – Ipofisaria, Policlinico Universitario A. Gemelli, Roma

PROVIDER E SEGRETERIA ORGANIZZATIVA



Provider Standard accreditato presso la Commissione Nazionale ECM - ID 680

Via Flaminia, 54 | 00196 Roma

Tel. 06 4061370 | Fax 06 3242600 | E-Mail: info@dotcomeventi.com | www.dotcomeventi.com

ISCRIZIONI

Per iscriversi collegarsi al sito www.dotcomeventi.com

La partecipazione all'evento è gratuita

ECM 680 - 363947

Assegnati n. 10 crediti formativi ECM

L'evento rientra nel Piano Formativo ECM anno 2022 della DOTCOM Srl ed è rivolto alle figure professionali di:

- **Medico - Chirurgo:** Anatomia Patologica, Chirurgia Generale, Endocrinologia, Gastroenterologia, Genetica Medica, Malattie Metaboliche e Diabetologia, Medicina Interna, Medicina Nucleare, Neurorochirurgia, Neuroradiologia, Oftalmologia, Otorinolaringoiatria, Patologia Clinica (Laboratorio di Analisi Chimico- Cliniche e Microbiologia), Radiodiagnostica, Radioterapia.
- **Infermiere**

OBIETTIVO FORMATIVO

Documentazione clinica. Percorsi clinico-assistenziali diagnostici e riabilitativi, profili di assistenza - profili di cura

Con la sponsorizzazione non condizionante di



PitNETs and aggressive pituitary adenomas



ROME

24th 25th

November 2022

Hotel Donna Camilla Savelli

Via Garibaldi 27 Roma



UNIVERSITÀ
CATTOLICA
del Sacro Cuore

Con il patrocinio di

Gemelli



Fondazione Policlinico Universitario Agostino Gemelli IRCCS
Università Cattolica del Sacro Cuore



sie Società Italiana
Endocrinologia

RESPONSABILE SCIENTIFICO
Laura De Marinis

www.ipofisicrescitadintorni.it

Arwork: Simona Reniè - Stampa: Arti Grafiche Vincèrò Srl

1st DAY | Thursday, 24th November 2022

13.00 Registration

13.30 Introduction: L. De Marinis

Welcome Speech

G. Fioroni, Vice Presidente Istituto "G. Toniolo", già Ministro dell'Istruzione

D. Lauro, Coordinatore SIE Lazio

A. Lenzi, Prof. Ordinario di Endocrinologia "Sapienza" Università di Roma,
Presidente Comitato di Biosicurezza PdCM

C. Motta, Referente Regionale AME Lazio

A. Olivi, Direttore UOC Neurochirurgia

Fondazione Pol. Universitario A. Gemelli IRCCSS, U.C.S.C.

A. Pontecorvi, Direttore Dipartimento Universitario di Scienze Medico-Chirurgiche Traslazionali
Fondazione Pol. Universitario A. Gemelli IRCCSS, U.C.S.C.

L. Festa, Presidente "ANIP"

PRESIDENTIALE LECTURE

Chairmen: A. Lenzi, A. Pontecorvi

14.00 One year in acromegaly - A. Giustina

I SESSION: New molecular knowledge and acquisitions on PitNETs: an update

Part 1

Chairmen: D. Ferone, M. L. Jaffrain-Rea, M. C. Zatelli

14.20 Universal nomenclature of neuroendocrine neoplasia: news from the WHO - G. Rindi

14.40 Clinical implications of the new WHO classification on the management of PitNET patients - A. Bianchi

15.00 How to standardize the diagnostic approach to pituitary neuroendocrine tumours (PitNETs) - S. Ascoli

15.30 New tools for precision medicine in pituitary tumors - M. Puig Domingo

Part 2

Chairmen: G. Arnaldi, E. De Menis, S. Grottoli

16.00 Aggressive pituitary tumours & carcinomas: Medical treatment beyond temozolomide G. Raverot

16.30 News on Pituitary proteomics - G. Grande, D. Milardi

16.50 Untangling metabolic pathways in PitNETs - D. De Alcubierre, A. M. Isidori

17.10 Discussion on topics

18.00 Conclusions

2nd DAY | Friday, 25th November 2022

8.10 Registration

LECTURE

Chairmen: V. Toscano, P. Zuppi

08.40 Pros and cons of rhGH hormone replacement therapy in adult patients with GHD M. Caputo

LECTURE

Chairmen: E. Ghigo, C. Scaroni

09.00 Prolactinoma, 15 years after the first Consensus - F. Casanueva

III SESSION: Round Table

Role of pituitary center of excellence in defining the nomenclature of pituitary neoplasia

Part 1

Chairmen: E. Capoluongo, G. Mantovani, M. Zollino

09.30 The point of view of the geneticist - G. L. Scaglione

09.50 The point of view of the pathologist - L. Poliani

10.10 The point of view of the translational medicine expert - F. Gatto

10.30 Discussion on topics

10.50 Coffee break

Part 2

Chairmen: A. Bianchi, F. Ferràù, G. Vitale

11.10 The point of view of the radiologist - T. Tartaglione

11.30 The point of view of the nuclear medicine expert - C. Caldarella

11.50 The point of view of the neurosurgeon - F. Doglietto

12.10 The point of view of the radiotherapist - C. Mazzarella, G. Minniti

12.30 The point of view of the bone metabolism specialist - S. Frara, A. Spada

12.50 The point of view of the coordinator of the pathway of pituitary pathology - L. Lauretti

13.00 Discussion on topics

13.20 Lunch

IV SESSION: Round Table

Pituitary adenomas Vs PitNETs in the real life: impact on endocrine management

Chairmen: P. Gargiulo, A. G. Lania, A. Scoppola

14.20 ACTH secreting adenoma Vs PitNET - R. Pivonello

Discussant: R. Baldelli

14.40 GH secreting adenoma Vs PitNET - A. Giampietro

Discussant: F. Doglietto

15.00 Not secreting adenoma Vs PitNET - P. Maffei

Discussant: A. Scoppola

15.20 Prolactin secreting adenoma Vs PitNET - S. Chiloiro

Discussant: M. Poggi

15.40 Discussion on topics

16.00 Closing remarks

CME Evaluation

FACULTY

Giorgio Arnaldi, Ancona
Sofia Ascoli, Bologna
Roberto Baldelli, Roma
Antonio Bianchi, Roma
Carmelo Caldarella, Roma
Ettore Domenico Capoluongo, Roma
Marina Caputo, Novara
Felipe Casanueva, Santiago De Compostela
Sabrina Chiloiro, Roma
Dario De Alcubierre, Roma
Laura De Marinis, Roma
Ernesto De Menis, Treviso
Francesco Doglietto, Roma
Diego Ferone, Genova
Francesco Ferràù, Messina
Lucia Festa, Roma
Giuseppe Fioroni, Roma
Stefano Frara, Milano
Patrizia Gargiulo, Roma

Federico Gatto, Genova
Ezio Ghigo, Torino
Roberto Baldelli, Roma
Antonella Giampietro, Roma
Andrea Giustina, Milano
Giuseppe Grande, Padova
Silvia Grottoli, Torino
Andrea Isidori, Roma
Marie Lise Jaffrain - Rea, I'Aquila
Giovanni Luca Scaglione, Roma
Carla Scaroni, Padova
Alessandro Scoppola, Roma
Davide Lauro, Roma
Andrea Lenzi, Roma
Pietro Maffei, Padova
Vincenzo Toscano, Roma
Giovanna Mantovani, Milano
Ciro Mazzarella, Roma
Lucia Festa, Roma
Giuseppe Fioroni, Roma
Stefano Frara, Milano
Patrizia Gargiulo, Roma

Rosario Pivonello, Napoli
Maurizio Poggi, Roma
Luigi Poliani, Brescia
Alfredo Pontecorvi, Roma
Manuel Puig-Domingo, Barcellona
Gerald Raverot, Lione
Guido Rindi, Roma
Giovanni Luca Scaglione, Roma
Carla Scaroni, Padova
Alessandro Scoppola, Roma
Antonio Spada, Roma
Tommaso Tartaglione, Roma
Vincenzo Toscano, Roma
Giovanni Vitale, Milano
Maria Chiara Zatelli, Ferrara
Marcella Zollino, Roma
Paolo Zuppi, Roma